What is the preferred ACE inhibitor or angiotensin receptor blocker for a patient with diabetes mellitus and heart failure?

Best ACEI or ARB for Diabetes with Heart Failure

Either an ACE inhibitor or ARB is appropriate for patients with diabetes and heart failure, with no single agent proven superior, but ACE inhibitors should be considered first-line based on stronger cardiovascular outcome data in this population.

Primary Recommendation

For patients with diabetes mellitus and heart failure, initiate an ACE inhibitor or ARB at the maximum tolerated dose as foundational therapy. 1 Both drug classes are recommended in contemporary guidelines, though the evidence base differs slightly between them.

ACE Inhibitors vs ARBs: The Evidence

• ACE inhibitors have demonstrated consistent reductions in all-cause mortality (13% reduction), cardiovascular death (19% reduction), myocardial infarction (23% reduction), and heart failure hospitalization (35% reduction) in patients with diabetes and hypertension 2

• ARBs show equivalent efficacy to ACE inhibitors for blood pressure control and stroke prevention, but meta-analyses suggest they may not provide the same magnitude of benefit for mortality and major cardiovascular events in diabetic patients 2, 3

• The ONTARGET trial demonstrated that telmisartan (an ARB) was non-inferior to ramipril (an ACE inhibitor) for cardiovascular outcomes in high-risk patients, including those with diabetes 4, 3

• In patients with type 2 diabetes and nephropathy specifically, ARBs (irbesartan, losartan) have proven renoprotective effects and are recommended 1

Practical Implementation Algorithm

Step 1: Initial Drug Selection

Start with an ACE inhibitor as first-line therapy unless contraindicated or not tolerated 1, 5:

• ACE inhibitors are preferred based on stronger mortality data in diabetic populations 2
• Titrate to maximum approved doses used in clinical trials (e.g., ramipril 10 mg daily, enalapril 10-20 mg twice daily) 1

Step 2: If ACE Inhibitor Not Tolerated

Switch to an ARB if the patient develops ACE inhibitor-related cough or angioedema 1:

• ARBs are equally effective alternatives when ACE inhibitors cannot be used 1, 4
• Use maximum tolerated doses (e.g., losartan 100 mg daily, valsartan 160 mg twice daily) 1

Step 3: Monitoring Protocol

Monitor serum creatinine and potassium within 2-4 weeks of initiation or dose increase 1:

• Continue therapy unless creatinine rises >30% within 4 weeks 1
• Manage hyperkalemia with dietary modification, diuretic adjustment, or potassium binders rather than immediately stopping the RAAS inhibitor 1
• Continue ACE inhibitor/ARB even when eGFR falls below 30 mL/min/1.73 m² 1

Critical Considerations for Heart Failure Patients

Heart Failure with Reduced Ejection Fraction (HFrEF)

Patients with diabetes, HFrEF, and LVEF ≤40% require quadruple foundational therapy 1, 6:

1. SGLT2 inhibitor (dapagliflozin or empagliflozin) 1
2. Angiotensin receptor-neprilysin inhibitor (ARNI) is preferred over ACE inhibitor/ARB 1, 7
3. Beta-blocker 1
4. Mineralocorticoid receptor antagonist 1

• If ARNI is not available or tolerated, use ACE inhibitor or ARB as second choice 1, 7
• ACE inhibitors and ARBs show equivalent mortality benefits in HFrEF patients with diabetes 1

Post-Myocardial Infarction

Start an ACE inhibitor within 24 hours of ST-elevation MI in patients with diabetes who have heart failure, left ventricular dysfunction, or both 1:

• Continue long-term for secondary prevention 1
• ARBs are appropriate alternatives if ACE inhibitors are not tolerated 1

Important Caveats

What NOT to Do

• Never combine ACE inhibitor + ARB + direct renin inhibitor 1 - this triple combination increases adverse events without benefit
• Avoid ACE inhibitor + ARB dual therapy for hypertension management 1, 4 - ONTARGET showed increased adverse events without cardiovascular benefit
• Do not use thiazolidinediones or saxagliptin in patients with heart failure and diabetes 1 - these increase heart failure hospitalization risk

Special Populations

For patients with diabetes, CKD, and albuminuria (ACR ≥30 mg/g):

• ACE inhibitor or ARB is strongly recommended and should be titrated to maximum tolerated dose 1
• Add nonsteroidal MRA (finerenone) if ACR ≥30 mg/g and potassium is normal 1

For pregnant or pregnancy-planning women:

• Discontinue ACE inhibitors and ARBs immediately 1 - both are teratogenic

Bottom Line

No specific ACE inhibitor or ARB has proven superiority over others within the same class for patients with diabetes and heart failure. 1, 2 The key is to:

1. Use an ACE inhibitor first (stronger mortality data) 5, 2
2. Switch to ARB only if ACE inhibitor not tolerated 1
3. Titrate to maximum approved doses 1
4. Consider ARNI over ACE inhibitor/ARB in HFrEF patients 1, 7
5. Always combine with SGLT2 inhibitor in eligible patients 1